Cholinesterase inhibitor use in geriatric outpatients with dementia

American Journal of Health-System Pharmacy

Volumn 62, Issue 9, 2005, Pages 923-926

  Linnebur, Sunny A ^a,b   Ruscin, J Mark ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OXYBUTYNIN; RIVASTIGMINE; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGED; ARTICLE; CLINICAL PRACTICE; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; DIARRHEA; DRUG USE; FEMALE; FUNCTIONAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENESCENCE; VOMITING;

EID: 17844377962     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.9.923     Document Type: Article

References (17)

1. Cummings JL. Alzheimer's disease. N Engl J Med. 2004; 351:56-67.
2. Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med. 2003; 138:400-10.
3. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998; 88:1337-42.
4. Lanctot KL, Herrmann N, Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ. 2003; 169:557-64.
5. Trinh NH, Hoblyn J, Mohanty S et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003; 289:210-6.
6. DeKosky S. Early intervention is key to successful management of Alzheimer disease. Alzheimer Dis Assoc Disord. 2003; 17(suppl 4):S99-104.
7. Luis CA, Loewenstein DA, Acevedo A et al. Mild cognitive impairment: directions for future research. Neurology. 2003; 61:438-44.
8. Blass J. Pathophysiology of the Alzheimer's syndrome. Neurology. 1993; 43(suppl 4):S25-38.
9. Watkins PB, Zimmerman HJ, Knapp MJ et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA. 1994; 271:992-8.
10. Lee K, ed. Tacrine (drug evaluation). In: Klasco RK, ed. DRUGDEX system. Greenwood Village, CO: Thomson MICROMEDEX; edition expired 2004 Sep.
11. Aricept (donepezil hydrochloride) package insert. Teaneck, NJ: Eisai Inc.; 2002 Aug.
12. Exelon (rivastigmine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2004 Jun.
13. Reminyl (galantamine hydrobromide) package insert. Titusville, NJ: Janssen Pharmaceutica; 2003 Mar.
14. Wilcock G, Howe I, Coles H et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003; 20:777-89.
15. Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003; 289:2819-26.
16. Shumaker SA, Legault C, Rapp SR et al Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289:2651-62.
17. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopheral, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997; 336:1216-22.